FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) announced on April 4 that subjects and doctors using this device in a clinical trial of the "conversational dementia diagnosis support AI system". We report that the analysis of conversation data with is started.

　In this clinical trial, subjects will be interviewed by a doctor and undergo neuropsychological tests (such as the MMSE) to diagnose dementia.Compare the results of analyzing the text data of the conversation at the time of the interview with the conversational dementia diagnosis support AI system and the results of the neuropsychological test, and use the analysis by this system as an alternative to the neuropsychological test in clinical practice. Check if is possible.Conventional neuropsychological tests are difficult to perform unless you are a doctor with specialized knowledge of dementia treatment, and the tests take time, which puts a heavy burden on both medical staff and patients. It was.If an alternative to the conversational dementia diagnosis support AI system becomes possible, doctors other than specialists will be able to diagnose dementia, which will lead to increased opportunities for patients to receive a diagnosis and early detection and treatment of dementia. I will.

　FRONTEO will work toward the early acquisition of manufacturing and marketing approval so that this system can be used in clinical practice as soon as possible.

■ Conversational dementia diagnosis support systemabout　URL: https://lifescience.fronteo.com/aidevice/dementia/
The conversational dementia diagnosis support system (AI medical device) uses FRONTEO's original natural language analysis AI "Concept Encoder (registered trademark: conceptencoder, reading: concept encoder)" between the patient and the doctor. It is a system that can screen for cognitive dysfunction from daily conversation for about 5 minutes.We believe that this system can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which is facing a super-aging society. I will. FRONTEO entered into a business alliance agreement with Kyowa Yakuhin Kogyo Co., Ltd., which aims to become a CNS (central nervous system) total solution company, in June 10, aiming for early commercialization and early market penetration in the medical field.Patent registration number: Patent No. 2020

■ About Concept Encoder　URL:https://lifescience.fronteo.com/technology/conceptencoder/

"Concept Encoder (registered trademark: concept encoder, reading: concept encoder)" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■FRONTEOabout　URL:https://www.fronteo.com/

FRONTEO uses the in-house developed AI engine "KIBIT" and "concept encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, with a focus on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and OSINT from 8, and created by using AI to "turn text data into knowledge". We contribute to solving various corporate issues such as drug support, dementia diagnosis support, financial, human resources, and sales support. Listed on TSE Mothers on June 2014, 2007. January 6 Obtained a first-class medical device manufacturing and sales license (permit number: 26B2021X1).The capital is 13 thousand yen (as of March 1, 10350).

* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.